XNAS · Healthcare · Biotechnology
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -1.53 | -1.82 | -18.95% | $10.9M | ❌ Miss | -0.74% | -10.84% | — |
| 2026-03-12 | Q4 2025 | -3.20 | -1.78 | +44.37% | $21.8M | ✅ Beat | +3.40% | +6.37% | +10.15% |
| 2025-11-06 |
| Q3 2025 |
| -2.81 |
| -1.87 |
| +33.45% |
| $11.8M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-12 | Q4 2024 | -0.19 | -0.15 | +21.05% | $29.2M | ✅ Beat | -0.56% | +9.41% | -24.67% |
| 2024-11-07 | Q3 2024 | -0.21 | -0.18 | +14.29% | $24.1M | ✅ Beat | +2.19% | -14.60% | -26.28% |
| 2024-03-04 | Q4 2023 | -0.21 | -0.22 | -4.76% | $23.9M | ❌ Miss | — | — | — |
| 2023-11-07 | Q3 2023 | -0.20 | -0.19 | +5.00% | $24.1M | ✅ Beat | -8.76% | -6.93% | -7.41% |
| 2023-08-08 | Q2 2023 | -0.28 | -0.27 | +3.57% | $20.5M | ✅ Beat | -8.94% | -19.07% | -40.60% |
Showing last 8 quarters.